Top

Current Treatment Options in Gastroenterology

Published in:

01-06-2021 | Care | Liver (J Bajaj, Section Editor)

Strategies to Improve Delivery of Cirrhosis Care

Authors: Akshata Moghe, MD PhD, Vera Yakovchenko, MPH, Timothy Morgan, MD, Heather McCurdy, MSN NP-C, Dawn Scott, MS PA-C, Karine Rozenberg-Ben-Dror, PharmD, Shari Rogal, MD MPH

Published in: Current Treatment Options in Gastroenterology | Issue 2/2021

Abstract

Purpose of review

This review provides an overview of the current state of research around improving healthcare delivery for patients with cirrhosis in the outpatient, inpatient, and transitional care settings.

Recent findings

Recent studies have broadly employed changes to the model of care delivery, team composition, and technology to improve cirrhosis care. In the outpatient setting, approaches have included engaging caregivers, patient navigators, and non-physicians and using virtual care, smartphone applications, and wearables. Inpatient care approaches have focused on the role of interdisciplinary teams, education interventions, and changes to the medical record system, while post-discharge interventions have included day hospitals and care coordinator interventions. This review also describes the Veterans Health Administration’s novel, population-level approach to delivery of cirrhosis care, and addressed how the pandemic has impacted the delivery of cirrhosis care.

Summary

Comprehensive, evidence-based approaches to delivering high-quality cirrhosis care continue to evolve to meet the needs of a growing population in an ever-changing healthcare environment.

Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36(1):227–42. https://doi.org/10.1053/jhep.2002.34734.CrossRefPubMed

Kardashian A, Patel AA, Aby ES, Cusumano VT, Soroudi C, Winters AC, et al. Identifying quality gaps in preventive care for outpatients with cirrhosis within a large, academic health care system. Hepatol Commun. 2020;4(12):1802–11. https://doi.org/10.1002/hep4.1594.CrossRefPubMedPubMedCentral

•• Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, et al. Development of quality measures in cirrhosis by the practice metrics committee of the American Association for the Study of Liver Diseases. Hepatology. 2019;69(4):1787–97. https://doi.org/10.1002/hep.30489 This guidance provides standard definitions of quality measures that can be used as the backbone of quality improvement programs.CrossRefPubMed

•• Tapper EB, Hao S, Lin M, Mafi JN, McCurdy H, Parikh ND, et al. The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers. Hepatology. 2020;71(1):225–34. https://doi.org/10.1002/hep.30695 This study demonstrated the importance of advanced practice providers in the delivery of high-quality cirrhosis care.CrossRefPubMed

Rosenblatt R, Yeh J, Gaglio PJ. Long-term management: modern measures to prevent readmission in patients with hepatic encephalopathy. Clin Liver Dis. 2020;24(2):277–90. https://doi.org/10.1016/j.cld.2020.01.007.CrossRefPubMed

Singal AG, Tiro JA, Marrero JA, McCallister K, Mejias C, Adamson B, et al. Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma. Gastroenterology. 2017;152(3):608–15 e4. https://doi.org/10.1053/j.gastro.2016.10.042.CrossRefPubMed

•• Su GL, Glass L, Tapper EB, Van T, Waljee AK, Sales AE. Virtual consultations through the veterans administration SCAN-ECHO project improves survival for veterans with liver disease. Hepatology. 2018;68(6):2317–24. https://doi.org/10.1002/hep.30074 This study demonstrated that virtual care consulation resulted in improved survival for Veterans with liver disease.CrossRefPubMed

Stotts MJ, Grischkan JA, Khungar V. Improving cirrhosis care: The potential for telemedicine and mobile health technologies. World J Gastroenterol. 2019;25(29):3849–56. https://doi.org/10.3748/wjg.v25.i29.3849.CrossRefPubMedPubMedCentral

Marciano S, Haddad L, Plazzotta F, Mauro E, Terraza S, Arora S, et al. Implementation of the ECHO((R)) telementoring model for the treatment of patients with hepatitis C. J Med Virol. 2017;89(4):660–4. https://doi.org/10.1002/jmv.24668.CrossRefPubMed

10.

Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176(3):340–9. https://doi.org/10.1001/jamainternmed.2015.7667.CrossRefPubMed

11.

Yakovchenko V, Hogan TP, Houston TK, Richardson L, Lipschitz J, Petrakis BA, et al. Automated text messaging with patients in department of veterans affairs specialty clinics: cluster randomized trial. J Med Internet Res. 2019;21(8):e14750. https://doi.org/10.2196/14750.CrossRefPubMedPubMedCentral

12.

Bajaj JS, Thacker LR, Heuman DM, Fuchs M, Sterling RK, Sanyal AJ, et al. The stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58(3):1122–32. https://doi.org/10.1002/hep.26309.CrossRefPubMedPubMedCentral

13.

Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, et al. Validation of EncephalApp, smartphone-based stroop test, for the diagnosis of covert hepatic encephalopathy. Clin Gastroenterol Hepatol. 2015;13(10):1828–35 e1. https://doi.org/10.1016/j.cgh.2014.05.011.CrossRefPubMed

14.

Ganapathy D, Acharya C, Lachar J, Patidar K, Sterling RK, White MB, et al. The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. Liver Int. 2017;37(12):1843–51. https://doi.org/10.1111/liv.13494.CrossRefPubMed

15.

Bloom P, Wang T, Marx M, Tagerman M, Green B, Arvind A, et al. A smartphone app to manage cirrhotic ascites among outpatients: feasibility study. JMIR Med Inform. 2020;8(9):e17770. https://doi.org/10.2196/17770.CrossRefPubMedPubMedCentral

16.

Zhang QWP, Liu Y, Peng B, Zhou Y, Zhou Z, et al. A real-time wireless wearable electroencephalography system based on Support Vector Machine for encephalopathy daily monitoring. Int J Distrib Sens Netw. 2018;14:1–9.

17.

Duarte-Rojo A, Bloomer PM, Rogers RJ, Hassan MA, Dunn MA, Tevar AD, et al. Introducing EL-FIT (Exercise and Liver FITness): a smartphone app to prehabilitate and monitor liver transplant candidates. Liver Transpl. 2020. https://doi.org/10.1002/lt.25950.

18.

Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau N, et al. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014;48(4):e30–6. https://doi.org/10.1097/MCG.0b013e3182a87f70.CrossRefPubMed

19.

Ghaoui R, Friderici J, Desilets DJ, Lagu T, Visintainer P, Belo A, et al. Outcomes associated with a mandatory gastroenterology consultation to improve the quality of care of patients hospitalized with decompensated cirrhosis. J Hosp Med. 2015;10(4):236–41. https://doi.org/10.1002/jhm.2314.CrossRefPubMed

20.

Tapper EB. Tackling 30-day readmissions in patients with cirrhosis. Curr Hepatol Rep. 2018;17:8–14.CrossRef

21•.

Shinall MC Jr, Karlekar M, Martin S, Gatto CL, Misra S, Chung CY, et al. COMPASS: a pilot trial of an early palliative care intervention for patients with end-stage liver disease. J Pain Symptom Manag. 2019;58(4):614–622 e3. https://doi.org/10.1016/j.jpainsymman.2019.06.023 This research has started to change the paradigm of palliative care utilization for patients with cirrhosis.

22.

Tapper EB. Building effective quality improvement programs for liver disease: a systematic review of quality improvement initiatives. Clin Gastroenterol Hepatol. 2016;14(9):1256–65 e3. https://doi.org/10.1016/j.cgh.2016.04.020.

23.

Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Chang M, Lai M. A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14(5):753–9. https://doi.org/10.1016/j.cgh.2015.08.041.CrossRefPubMed

24.

Carbonneau M, Eboreime EA, Hyde A, Campbell-Scherer D, Faris P, Gramlich L, et al. The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial. BMC Health Serv Res. 2020;20(1):558. https://doi.org/10.1186/s12913-020-05427-8.CrossRefPubMedPubMedCentral

25.

Rawson TM, Bouri S, Allen C, Ferreira-Martins J, Yusuf A, Stafford N, et al. Improving the management of spontaneous bacterial peritonitis in cirrhotic patients: assessment of an intervention in trainee doctors. Clin Med (Lond). 2015;15(5):426–30. https://doi.org/10.7861/clinmedicine.15-5-426.CrossRef

26.

Lim N, Sanchez O, Olson A. Impact on 30-d readmissions for cirrhotic patients with ascites after an educational intervention: a pilot study. World J Hepatol. 2019;11(10):701–9. https://doi.org/10.4254/wjh.v11.i10.701.CrossRefPubMedPubMedCentral

27.

Mumtaz K, Issak A, Porter K, Kelly S, Hanje J, Michaels AJ, et al. Validation of risk score in predicting early readmissions in decompensated cirrhotic patients: a model based on the administrative database. Hepatology. 2019;70(2):630–9. https://doi.org/10.1002/hep.30274.CrossRefPubMed

28.

Gaspar R, Rodrigues S, Silva M, Costa-Moreira P, Morais R, Andrade P, et al. Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis. Dig Liver Dis. 2019;51(10):1423–9. https://doi.org/10.1016/j.dld.2019.03.016.CrossRefPubMed

29.

Kanwal F, Asch SM, Kramer JR, Cao Y, Asrani S, El-Serag HB. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016;64(2):569–81. https://doi.org/10.1002/hep.28558.CrossRefPubMed

30.

Rao BB, Sobotka A, Lopez R, Romero-Marrero C, Carey W. Outpatient telephonic transitional care after hospital discharge improves survival in cirrhotic patients. World J Hepatol. 2019;11(8):646–55. https://doi.org/10.4254/wjh.v11.i8.646.CrossRefPubMedPubMedCentral

31•.

Morales BP, Planas R, Bartoli R, Morillas RM, Sala M, Casas I, et al. HEPACONTROL. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis. Dig Liver Dis. 2018;50(1):76–83. https://doi.org/10.1016/j.dld.2017.08.024 This publication provides information about a successful intervention in the post-discharge period.

32.

Kimbell B, Murray SA, Byrne H, Baird A, Hayes PC, MacGilchrist A, et al. Palliative care for people with advanced liver disease: a feasibility trial of a supportive care liver nurse specialist. Palliat Med. 2018;32(5):919–29. https://doi.org/10.1177/0269216318760441.CrossRefPubMedPubMedCentral

33.

Cirrhosis Medical Home (CMH). ClinicalTrialsgov Identifier: NCT04581369.

34.

Belperio PS, Chartier M, Gonzalez RI, Park AM, Ross DB, Morgan TR, et al. Hepatitis C care in the Department of Veterans Affairs: building a foundation for success. Infect Dis Clin N Am. 2018;32(2):281–92. https://doi.org/10.1016/j.idc.2018.02.011.CrossRef

35.

Park A, Gonzalez R, Chartier M, Rogal S, Yakovchenko V, Ross D, et al. Screening and treating hepatitis C in the VA: achieving excellence using lean and system redesign. Fed Pract. 2018;35(7):24–9.PubMedPubMedCentral

36.

Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Gonzalez R, Park A, et al. Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2. Implement Sci. 2019;14(1):36. https://doi.org/10.1186/s13012-019-0881-7.CrossRefPubMedPubMedCentral

37.

Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Kirchner JE, Proctor EK, et al. The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. Implement Sci. 2017;12(1):60. https://doi.org/10.1186/s13012-017-0588-6.CrossRefPubMedPubMedCentral

38.

Rogal SS, Yakovchenko V, Morgan T, Bajaj JS, Gonzalez R, Park A, et al. Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans. Implement Sci. 2020;15(1):92. https://doi.org/10.1186/s13012-020-01050-7.CrossRefPubMedPubMedCentral

39.

Mahmud N, Hubbard RA, Kaplan DE, Serper M. Declining cirrhosis hospitalizations in the wake of the COVID-19 pandemic: a national cohort study. Gastroenterology. 2020;159(3):1134–6 e3. https://doi.org/10.1053/j.gastro.2020.05.005.CrossRefPubMedPubMedCentral

40.

Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73(2):441–5. https://doi.org/10.1016/j.jhep.2020.04.005.CrossRefPubMedPubMedCentral

41.

Serper M, Shaked A, Olthoff KM, Hoteit M, Appolo B, Reddy KR. A local response to COVID-19 for advanced liver disease: current model of care, challenges and opportunities. J Hepatol. 2020;73(3):708–9. https://doi.org/10.1016/j.jhep.2020.05.022.CrossRefPubMedPubMedCentral

42••.

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72(1):287–304. https://doi.org/10.1002/hep.31281 This paper gives real-world advice for managing care delivery during the COVID-19 pandemic.

43.

Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. https://doi.org/10.1016/j.jhepr.2020.100113.CrossRefPubMedPubMedCentral

44.

GD MN, Kaplan D, Serper M. Major shifts in outpatient cirrhosis care delivery attributable to the COVID-19 pandemic: a national cohort study. Hepatol Commun. 2020. https://doi.org/10.1002/hep4.1638.

45.

Serper M, Cubell AW, Deleener ME, Casher TK, Rosenberg DJ, Whitebloom D, et al. Telemedicine in liver disease and beyond: can the COVID-19 crisis lead to action? Hepatology. 2020;72(2):723–8. https://doi.org/10.1002/hep.31276.CrossRefPubMedPubMedCentral

Title: Strategies to Improve Delivery of Cirrhosis Care
Authors: Akshata Moghe, MD PhD
Vera Yakovchenko, MPH
Timothy Morgan, MD
Heather McCurdy, MSN NP-C
Dawn Scott, MS PA-C
Karine Rozenberg-Ben-Dror, PharmD
Shari Rogal, MD MPH
Publication date: 01-06-2021
Publisher: Springer US
Keywords: Care
Ascites
Encephalopathy
Published in: Current Treatment Options in Gastroenterology / Issue 2/2021
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-021-00345-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2021

EUS-FNA vs EUS-FNB for Pancreatic Lesions: Which Needle When to Use?

Reproductive Health in IBD Patients

Endoscopic Evaluation of Indeterminate Biliary Strictures: a Review

Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC)

Metabolomics in Advanced Liver Disease

Clinical Management of Oligopolyposis of Unknown Etiology

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage